Company intelligence / Profile preview
Hyperway Pharmaceutical
Chengdu, Sichuan, Chinahyperwaypharma.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Hyperway Pharmaceutical is a clinical-stage biotech company with its lead asset HBW-3220, a BTK C481S mutant inhibitor, in Phase IIa for chronic lymphocytic leukemia/SLL, showing a 100% objective response rate in early trials. Another program, HBW-004285, a Nav1.8 inhibitor for pain, is in Phase II.
- Therapeutic areas
- NeurologyPsychiatryInfectious DiseasesDermatologyOncologyOtherNephrologyImmunology
- Modalities
- Small moleculeNucleic acidOral peptideProtein degradationMolecular glue
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships disclosed yet but actively seeking collaborations globally for co-development/licensing opportunities.
Beyond the preview
Go deeper on Hyperway Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyperway Pharmaceutical.